Former Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three late-stage drugs saw their hopes dashed as 2020 drew to a close. The contingent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results